Olutasidenib

Olutasidenib

Clinical data
Trade names	Rezlidhia
Other names	FT-2102
License data	US DailyMed: Olutasidenib
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	US: ℞-only
Identifiers
CAS Number	1887014-12-1
PubChem CID	118955396
IUPHAR/BPS	10319
DrugBank	DB16267
ChemSpider	72380144
UNII	0T4IMT8S5Z
KEGG	D12483
ChEMBL	ChEMBL4297610
PDB ligand	PWV (PDBe, RCSB PDB)
Chemical and physical data
Formula	C18H15ClN4O2
Molar mass	354.79 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2
InChI InChI=InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1 Key:NEQYWYXGTJDAKR-JTQLQIEISA-N

Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia. Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is taken by mouth.

The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis.

Olutasidenib was approved for medical use in the United States in December 2022.

Medical uses

Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Society and culture

Names

Olutasidenib is the international nonproprietary name.

Further reading

• Liu X, Gong Y (2019). "Isocitrate dehydrogenase inhibitors in acute myeloid leukemia". Biomarker Research. 7: 22. doi:10.1186/s40364-019-0173-z. PMC 6806510. PMID 31660152.
• Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, et al. (November 2022). "Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial". The Lancet Haematology. 10 (1): e46–e58. doi:10.1016/S2352-3026(22)00292-7. PMID 36370742. S2CID 253471380.

External links

• "Olutasidenib". Drug Information Portal. U.S. National Library of Medicine.
• Clinical trial number NCT02719574 for "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation" at ClinicalTrials.gov